BACKGROUND: Increased reactivity of the insular cortex and decreased activity of the dorsal anterior cingulate cortex (ACC) are seen in functional imaging studies of posttraumatic stress disorder (PTSD), and may partly explain the persistent fear and anxiety proneness that characterize the disorder. A possible neurochemical correlate is altered function of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA). We report results from what we believe is the first study applying proton magnetic resonance spectroscopy ((1) H-MRS) to measure brain GABA in PTSD. METHODS: Thirteen adults with DSM-IV PTSD and 13 matched healthy control subjects underwent single voxel (1) H-MRS at 4 Tesla. GABA was measured in the right anterior insula and dorsal ACC, using Mescher-Garwood Point-Resolved Echo Spectroscopy Sequence (MEGAPRESS) spectral editing. Subjects were interviewed with the Structured Clinical Interview for DSM-IV and the Clinician Administered PTSD Scale, and also completed the State and Trait Anxiety Inventory. RESULTS: Insula GABA was significantly lower in PTSD subjects than in controls, and dorsal ACC GABA did not differ significantly between the groups. Insula GABA was not significantly associated with severity of PTSD symptoms. However, lower insula GABA was associated with significantly higher state and trait anxiety in the subject sample as a whole. CONCLUSIONS: PTSD is associated with reduced GABA in the right anterior insula. This preliminary evidence of the (1) H-MRS GABA metabolite as a possible biomarker of PTSD encourages replication in larger samples and examination of relations with symptom dimensions. Future studies also should examine whether insula GABA is a marker of anxiety proneness, cutting across clinical diagnostic categories.
BACKGROUND: Increased reactivity of the insular cortex and decreased activity of the dorsal anterior cingulate cortex (ACC) are seen in functional imaging studies of posttraumatic stress disorder (PTSD), and may partly explain the persistent fear and anxiety proneness that characterize the disorder. A possible neurochemical correlate is altered function of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA). We report results from what we believe is the first study applying proton magnetic resonance spectroscopy ((1) H-MRS) to measure brain GABA in PTSD. METHODS: Thirteen adults with DSM-IV PTSD and 13 matched healthy control subjects underwent single voxel (1) H-MRS at 4 Tesla. GABA was measured in the right anterior insula and dorsal ACC, using Mescher-Garwood Point-Resolved Echo Spectroscopy Sequence (MEGAPRESS) spectral editing. Subjects were interviewed with the Structured Clinical Interview for DSM-IV and the Clinician Administered PTSD Scale, and also completed the State and Trait Anxiety Inventory. RESULTS: Insula GABA was significantly lower in PTSD subjects than in controls, and dorsal ACC GABA did not differ significantly between the groups. Insula GABA was not significantly associated with severity of PTSD symptoms. However, lower insula GABA was associated with significantly higher state and trait anxiety in the subject sample as a whole. CONCLUSIONS:PTSD is associated with reduced GABA in the right anterior insula. This preliminary evidence of the (1) H-MRSGABA metabolite as a possible biomarker of PTSD encourages replication in larger samples and examination of relations with symptom dimensions. Future studies also should examine whether insula GABA is a marker of anxiety proneness, cutting across clinical diagnostic categories.
Authors: Rosane Gomez; Kevin L Behar; June Watzl; Stuart A Weinzimer; Barbara Gulanski; Gerard Sanacora; Julia Koretski; Elizabeth Guidone; Lihong Jiang; Ismene L Petrakis; Brian Pittman; John H Krystal; Graeme F Mason Journal: Biol Psychiatry Date: 2011-08-19 Impact factor: 13.382
Authors: Nicola De Stefano; Sridar Narayanan; Simon J Francis; Steve Smith; Marzia Mortilla; M Carmela Tartaglia; Maria L Bartolozzi; Leonello Guidi; Antonio Federico; Douglas L Arnold Journal: Arch Neurol Date: 2002-10
Authors: Matthew Geramita; Jan Willem van der Veen; Alan S Barnett; Antonina A Savostyanova; Jun Shen; Daniel R Weinberger; Stefano Marenco Journal: NMR Biomed Date: 2011-02-03 Impact factor: 4.044
Authors: Gerard Sanacora; Graeme F Mason; Douglas L Rothman; Fahmeed Hyder; James J Ciarcia; Robert B Ostroff; Robert M Berman; John H Krystal Journal: Am J Psychiatry Date: 2003-03 Impact factor: 18.112
Authors: Mohammed R Milad; Gregory J Quirk; Roger K Pitman; Scott P Orr; Bruce Fischl; Scott L Rauch Journal: Biol Psychiatry Date: 2007-08-20 Impact factor: 13.382
Authors: Christian E Waugh; Tor D Wager; Barbara L Fredrickson; Doug C Noll; Stephan F Taylor Journal: Soc Cogn Affect Neurosci Date: 2008-09-02 Impact factor: 3.436
Authors: Lisa M Shin; Natasha B Lasko; Michael L Macklin; Rachel D Karpf; Mohammed R Milad; Scott P Orr; Jared M Goetz; Alan J Fischman; Scott L Rauch; Roger K Pitman Journal: Arch Gen Psychiatry Date: 2009-10
Authors: Kimberly A Arditte Hall; Sumaiya E DeLane; George M Anderson; Tiffany R Lago; Rachel Shor; Weiwei Wang; Ann M Rasmusson; Suzanne L Pineles Journal: Psychopharmacology (Berl) Date: 2021-02-23 Impact factor: 4.530
Authors: Marisa M Silveri; Julia Cohen-Gilbert; David J Crowley; Isabelle M Rosso; J Eric Jensen; Jennifer T Sneider Journal: Alcohol Clin Exp Res Date: 2014-02-11 Impact factor: 3.455
Authors: Remmelt R Schür; Luc W R Draisma; Jannie P Wijnen; Marco P Boks; Martijn G J C Koevoets; Marian Joëls; Dennis W Klomp; René S Kahn; Christiaan H Vinkers Journal: Hum Brain Mapp Date: 2016-05-04 Impact factor: 5.038